Telemetry / Cardiac

Key takeaways

• At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
• The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
• A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Nursing implications

• Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

• Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Sixty percent of patients in the included studies received home mechanical ventilation.
• Survival improved progressively over time in both ventilated and non-ventilated groups.
• As respiratory survival improved, cardiac and other causes accounted for a larger share of deaths.

Nursing implications

• During admissions and handoffs, verify the established ventilation, airway-clearance, and cardiac-monitoring plan and coordinate concerns with the multidisciplinary team.

Limitations & cautions

• Abstract-only summary. This was a study-level meta-analysis of heterogeneous observational survival reports; the ventilated and non-ventilated groups were not randomized, so associations should not be interpreted as treatment effects.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The document focuses on scenarios that are not well represented in antiarrhythmic-drug trials.
• Its practical advice combines the available evidence with multidisciplinary expert experience.
• The abstract does not support applying one antiarrhythmic approach across all understudied situations.

Nursing implications

• Verify the scenario-specific treatment and monitoring plan, then follow provider orders and local medication-safety protocols.

Limitations & cautions

• Abstract-only summary. The abstract does not enumerate individual recommendations, patient groups, drug choices, doses, or monitoring thresholds.
• AI-summarized from the linked source. Review the original statement before applying to practice.

Key takeaways

• Ambulatory blood pressure findings came from only two trials and had moderate certainty.
• Blood pressure response improved, but control-target achievement did not differ significantly.
• Evidence concerning major adverse events was very low certainty.

Nursing implications

• Interpret blood pressure trends in the context of the prescribed regimen; this review does not identify one best combination for every patient.

Limitations & cautions

• Abstract-only summary. Comparators varied, long-term data were limited, and Asian populations predominated. The review does not establish superior cardiovascular outcomes.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The randomized study enrolled 80 patients at two hospitals.
• Slow deep breathing was tested as an adjunct during chest-tube removal after CABG.
• Mean pain during removal was lower with breathing exercises than with standard care.
• Anxiety and post-removal pain were also lower, but the abstract does not provide every effect estimate.

Nursing implications

• Where the unit permits it, explain and rehearse slow deep breathing before removal, coach the patient through the procedure, and reassess pain and anxiety afterward. Treat it as an adjunct, not a replacement for prescribed analgesia or procedural monitoring.

Limitations & cautions

• The trial was small and conducted at two hospitals, with self-reported pain and anxiety. The abstract does not describe blinding, the exact breathing protocol, all effect sizes, analgesic use, or longer-term outcomes, limiting transfer to other settings.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review included nine randomized placebo-controlled trials and 6,239 adults without diabetes.
• Mean percentage body-weight change favored semaglutide by 12.04 percentage points.
• Waist circumference and C-reactive protein also decreased relative to placebo.
• Serious adverse events did not differ significantly, but the review called for longer-term safety and efficacy data.

Nursing implications

• Confirm the product, prescribed dose and titration, indication, administration technique, missed-dose plan, tolerance, and follow-up. Report concerning symptoms or inability to maintain hydration and nutrition through the prescribing team's established pathway.

Limitations & cautions

• The abstract reports nine placebo-controlled trials but does not establish long-term outcomes across all clinical populations. The serious-adverse-event estimate was imprecise, and pooled efficacy should not be used to predict an individual's response or support an unprescribed dose change.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The statement fills gaps left by guidance focused on more common inherited arrhythmia syndromes.
• Recommendations integrate available evidence with expert opinion using European Society of Cardiology consensus methods.
• The framework covers pharmacologic therapy, left cardiac sympathetic denervation, and selective implantable-cardioverter-defibrillator use.
• Pediatric and fetal presentation, molecular autopsy, family screening, and multidisciplinary specialized care receive specific attention.

Nursing implications

• For a patient with a known or suspected inherited arrhythmia syndrome, reconcile the exact diagnosis, symptoms, rhythm history, medications, implanted-device status, family history, and specialist emergency plan. Escalate syncope, palpitations with instability, seizures of uncertain cause, or concerning rhythm change urgently.

Limitations & cautions

• These very rare conditions have limited prospective evidence, so the statement combines evidence with expert consensus. The PubMed abstract summarizes the framework but does not provide condition-specific recommendation classes, doses, or algorithms; readers should consult the full statement.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Seven studies included 14,884 patients with recent ischemic stroke, nonvalvular atrial fibrillation, and large-artery atherosclerosis.
• Combined anticoagulant and antiplatelet therapy did not significantly reduce recurrent ischemic stroke versus anticoagulation alone.
• All-cause mortality was not significantly different between strategies.
• Major bleeding was higher with combined therapy (RR 1.49, 95% CI 1.04 to 2.15).

Nursing implications

• During medication reconciliation, identify concurrent anticoagulant and antiplatelet therapy, verify the documented indication and duration, assess for bleeding, and escalate discrepancies or new bleeding promptly. Do not independently stop either drug.

Limitations & cautions

• The meta-analysis combined randomized and observational evidence, so residual confounding and differences among studies remain possible. It addresses a specific population with stroke, atrial fibrillation, and large-artery atherosclerosis and does not cover every indication for combined therapy.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The update included 15 randomized trials involving 4,971 participants.
• Synthetic versus biological patches probably made little or no difference in long-term stroke or death.
• Long-term ipsilateral stroke, any stroke, and restenosis outcomes also showed little or no clear difference, but certainty was low.
• Evidence for perioperative ipsilateral stroke, arterial rupture, and long-term pseudoaneurysm was very uncertain.

Nursing implications

• Confirm the operative details during handoff, perform ordered neurologic and vascular assessments, inspect the neck and incision, and promptly escalate new deficit, swelling, bleeding, airway concern, or perfusion change. Do not use patch material alone to infer a lower-risk recovery.

Limitations & cautions

• Many trials were small, events were uncommon, confidence intervals were wide, and some studies had design limitations. Certainty ranged from moderate for long-term stroke or death to very low for several perioperative and structural outcomes.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review synthesized 67 case reports or small case series rather than comparative trials.
• Complications fell into septal, vascular, valvular or subvalvular, mechanical or lead-related, and electrophysiologic categories.
• Delayed perforation could present with arrhythmia, thromboembolism, or tamponade.
• Normal electrical device parameters did not rule out clinically important structural complications.

Nursing implications

• After left bundle branch area pacing, connect new hemodynamic change, arrhythmia, ischemia-like symptoms, or neurologic concern with the recent procedure and escalate promptly. Continue ordered rhythm and device monitoring while the team evaluates for structural as well as electrical causes.

Limitations & cautions

• The evidence consists of case reports and small case series, which cannot estimate complication incidence or compare management strategies. Publication bias likely favors unusual or severe events.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The trial randomized 170 adults with multivessel coronary disease who were eligible for both surgical approaches.
• One-month patient-reported physical recovery favored small-thoracotomy CABG by 2.9 SF-36 physical-component points.
• No deaths or strokes occurred in either group through 12 months; one major cardiac or cerebrovascular event occurred in the minimally invasive group.
• Results apply to selected patients treated by experienced teams, and the study was funded by Medtronic.

Nursing implications

• Confirm the operative approach during handoff and use its approved incision, mobility, pain, respiratory, and activity pathway. Track functional recovery and escalate unexpected cardiopulmonary, wound, or neurologic findings without assuming the smaller incision removes standard CABG risks.

Limitations & cautions

• The trial was open label, enrolled 170 highly selected patients suitable for either approach, and was performed by experienced teams. It was funded by Medtronic, most participants were men, and uncommon safety outcomes cannot be ruled out from zero events in this sample.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review included 16 randomized trials with 6,611 participants treated for at least 12 weeks.
• Compared with placebo, dual GLP-1/glucagon receptor agonists reduced body weight by a pooled 7.44% and 7.27 kg.
• Weight loss was accompanied by improvements across the cardiometabolic risk factors assessed in the review.
• Versus selective GLP-1 receptor agonists, the clearest additional pooled difference reported in the abstract was lower triglycerides by 0.28 mmol/L.

Nursing implications

• When a patient is receiving a prescribed incretin-based therapy, document the exact agent and indication and follow the approved pathway for weight, glycemic, hemodynamic, laboratory, and adverse-effect monitoring. Do not treat pooled changes in risk markers as proof of fewer cardiovascular events.

Limitations & cautions

• The abstract reports risk-factor outcomes rather than cardiovascular events, mortality, or long-term safety. Trials varied by dose and indication, and the authors call for large-scale outcome studies before broader conclusions about clinical benefit.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The double-blind trial enrolled 955 adults across 33 hospitals in 10 countries before elective cardiac surgery.
• Participants received 1000 mg intravenous iron or placebo 1 to 26 weeks before surgery.
• In-hospital red-cell transfusion was less frequent with intravenous iron, with a relative risk of 0.90.
• The adjusted improvement in days alive and at home was one day, with no detected difference in major complications or hospital length of stay.

Nursing implications

• For a patient enrolled in a preoperative anemia pathway, verify the ordered iron formulation, dose, timing, required laboratory data, and infusion-monitoring steps. Continue standard postoperative bleeding and transfusion surveillance; preoperative treatment does not eliminate the need for individualized blood-management decisions.

Limitations & cautions

• The primary outcome difference was small, transfusion remained common in both groups, and the trial found no difference in major complications or hospital stay. Results apply to anemic adults undergoing elective cardiac surgery and do not establish benefit for emergency surgery or patients meeting the trial's exclusions.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review pooled individual participant data from four randomized trials involving 2,944 adults with prior spontaneous intracerebral hemorrhage.
• Intensive blood-pressure lowering reduced first recurrent stroke, with an adjusted hazard ratio of 0.62 compared with control.
• The reduction was driven mainly by fewer recurrent intracerebral hemorrhages, and no excess of serious adverse events was identified.
• Treatment effects were consistent across prespecified subgroups, but the analysis does not supply one bedside target for every patient.

Nursing implications

• At transition and follow-up, reconcile antihypertensives, confirm the prescribed blood-pressure goal and home-monitoring plan, assess barriers to adherence, and use teach-back for stroke warning signs and when to contact the care team. Escalate symptomatic hypotension, persistent out-of-range readings, or new neurological findings.

Limitations & cautions

• Only four eligible trials contributed individual participant data, participants were predominantly Asian, and the included trials used different treatment strategies and targets. The meta-analysis supports long-term blood-pressure lowering but does not define one medication regimen or target for every survivor.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The event-driven phase 3 trial analyzed 350 patients assigned to ralinepag and 337 assigned to placebo.
• A first clinical-worsening event occurred in 18% with ralinepag and 36% with placebo, with a hazard ratio of 0.45.
• Adverse events prompted treatment discontinuation in 19% of the ralinepag group and 3% of the placebo group.
• The trial excluded data from 41 treated patients at sites in China because of regulatory and data-integrity concerns.

Nursing implications

• For a patient prescribed ralinepag, reconcile the full pulmonary-hypertension regimen and trend symptoms, function, blood pressure, heart rate, and ordered safety measures during titration. Escalate worsening cardiopulmonary status or treatment-limiting effects through the pulmonary-hypertension pathway.

Limitations & cautions

• The trial used a composite outcome, and the largest numerical differences were in disease progression, addition of prostacyclin-pathway therapy, and unsatisfactory long-term response rather than death alone. Forty-one treated patients from sites in China were excluded, and the findings apply to specialist-managed adults meeting the trial's pulmonary arterial hypertension criteria.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The multicenter trial enrolled 1,840 mechanically ventilated adults who remained unresponsive after cardiac-arrest resuscitation.
• Survival with a favorable 180-day functional outcome was 38.2% with conservative oxygen and 39.7% with liberal oxygen.
• The relative risk was 0.97 with a 95% confidence interval from 0.87 to 1.09.
• The trial compared specific oxygen protocols and does not support changing an individual patient's ordered targets without the treating team's direction.

Nursing implications

• Confirm the ordered post-arrest saturation range and oxygen-titration plan at handoff, trend oxygenation with ventilation and neurological findings, and document changes in support. Escalate hypoxemia, ventilator problems, or acute neurological or hemodynamic change through the unit pathway.

Limitations & cautions

• The trial studied unresponsive, mechanically ventilated adults in ICUs in Australia, New Zealand, and Ireland using two specific oxygen protocols. It does not establish the best target for patients outside those criteria, and the primary-outcome denominators were lower than the numbers assigned to each group.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The FIND-CKD trial randomized 1,584 adults without diabetes who had CKD and albuminuria while taking a renin-angiotensin system inhibitor.
• Finerenone reduced the mean annual eGFR decline by 0.7 mL/min/1.73 m² compared with placebo.
• The hazard ratio for the prespecified composite kidney or cardiovascular outcome was 0.77, with a 95% confidence interval from 0.60 to 0.99.
• Hyperkalemia and hyperkalemia-related discontinuation were more frequent with finerenone, making laboratory and medication monitoring central to safe use.

Nursing implications

• Before administration or medication teaching, reconcile finerenone with other therapies that affect potassium or kidney function and confirm the ordered laboratory schedule. Route elevated potassium, worsening kidney function, missed monitoring, or symptoms of concern to the prescribing team.

Limitations & cautions

• The primary outcome was eGFR slope rather than a patient-reported outcome, the cardiovascular component estimate was imprecise, and the trial enrolled a defined albuminuric CKD population already receiving renin-angiotensin system inhibition. The study was funded by Bayer, and results do not establish suitability for patients outside the eligibility criteria.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The trial randomized 236 adults with cardiovascular disease to home- or center-based rehabilitation.
• Both groups improved exercise capacity during six months of follow-up.
• Center-based rehabilitation produced larger exercise-capacity and blood-pressure improvements.
• Home-based rehabilitation remained a potentially useful option when center access was limited.

Nursing implications

• Assess referral status, transportation, work, caregiving, technology, and other barriers before discharge. Reinforce the prescribed rehabilitation setting and exercise limits, confirm blood-pressure follow-up, and use teach-back for symptoms that require stopping activity or seeking care.

Limitations & cautions

• The trial was conducted in one national setting, and the abstract does not describe blinding, adherence, crossover, adverse events, or cardiovascular events. Results may not generalize to different rehabilitation programs, patient groups, or health systems.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The multicenter trial randomized 392 adults to dapagliflozin and 392 to placebo around elective cardiac surgery.
• Acute kidney injury occurred in 28% with dapagliflozin and 52% with placebo during seven-day follow-up.
• Atrial fibrillation occurred in 45% of both groups, while reoperation occurred in 11% and 10%, respectively.
• The tested regimen comprised four 10-mg doses beginning one day before surgery.

Nursing implications

• When caring for a patient on a clinician-directed perioperative dapagliflozin pathway, verify the exact schedule, monitor ordered renal and hemodynamic measures, and escalate oliguria, worsening kidney function, hypotension, or medication discrepancies. Follow the approved fasting, diabetes, and perioperative medication protocol.

Limitations & cautions

• Follow-up for the primary outcome was seven days, 97% of participants were White, and the study was conducted at seven hospitals in the Netherlands. The abstract reports selected adverse events and does not establish longer-term renal, metabolic, or mortality outcomes.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The open-label trial randomized 1,000 adults with migraine and patent foramen ovale across 39 centers in China; 984 were included in the full analysis set.
• Aspirin, clopidogrel, and rivaroxaban were each non-inferior to metoprolol for the prespecified migraine responder outcome.
• Rivaroxaban produced a 78.4% responder rate versus 61.8% with metoprolol.
• No major bleeding events occurred, but the 12-week trial does not establish longer-term comparative safety.

Nursing implications

• When caring for a patient enrolled in a clinician-directed antithrombotic plan, reconcile the exact agent and indication, complete ordered bleeding and medication-safety assessments, and reinforce prescribed follow-up. Escalate bleeding, new neurologic symptoms, pregnancy concerns, or medication discrepancies promptly.

Limitations & cautions

• Treatment was open label, follow-up lasted 12 weeks, and participants with previous stroke, transient ischemic attack, intracranial hemorrhage, or medication contraindications were excluded. The trial was conducted in China and compared active treatments without a placebo group, limiting generalizability and long-term safety conclusions.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review pooled 18 randomized trials involving 15,560 adults hospitalized with acute heart failure.
• Heart-failure worsening or hospitalization was lower with in-hospital SGLT2-inhibitor initiation (RR 0.77, 95% CI 0.67 to 0.88; NNT 48).
• Diuretic efficiency, weight loss, NT-proBNP, and quality-of-life scores favored initiation during hospitalization.
• No increase was detected in acute kidney injury, hypotension, hypoglycemia, ketoacidosis, genitourinary infection, or other serious adverse events.

Nursing implications

• When an SGLT2 inhibitor is prescribed during an acute-heart-failure admission, reconcile the medication, trend the ordered volume and safety measures, and make the follow-up plan visible at discharge. A pooled absence of excess adverse events does not remove patient-specific contraindications or monitoring requirements.

Limitations & cautions

• This meta-analysis pooled trial-level evidence through February 2026. The all-cause mortality signal showed potential publication bias and weakened in sensitivity analysis, several outcomes did not differ significantly, and the authors call for longer-term confirmatory data.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The analysis followed older adults with chronic heart failure for three months after hospital discharge.
• The intervention paired usual care with nurse-led, age-friendly, graded support for recognizing and responding to symptoms.
• Self-care and task-execution trajectories improved more over time in the intervention group.
• The study assessed behavioral outcomes and does not establish an effect on hospitalization, mortality, or long-term disease control.

Nursing implications

• Use the approved heart-failure education pathway to review individualized symptoms, the prescribed response plan, and escalation contacts. Ask the patient to explain how they would respond to a change, revisit uncertain steps during follow-up, and communicate new or worsening symptoms through the heart-failure team.

Limitations & cautions

• This was a secondary analysis of a previously designed trial from a tertiary-hospital population, and the PubMed abstract does not report the analyzed sample size. Follow-up lasted three months, outcomes were self-reported or structured behavioral measures, and the analysis did not evaluate hospitalization, mortality, or long-term clinical benefit.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Eight randomized trials with 1,368 participants evaluated structured mobile health-supported cardiac rehabilitation.
• Compared with usual care, six-minute walk distance improved by a pooled mean of 22.99 meters.
• Peak oxygen uptake improved modestly versus center-based rehabilitation, but the comparison included few trials.
• Evidence certainty was low to moderate, and sparse safety events and short follow-up limited safety conclusions.

Nursing implications

• Confirm that a remote rehabilitation plan is clinician-directed and matches the patient's functional status, technology access, and monitoring needs. Reinforce prescribed symptom and activity tracking, review escalation instructions, and communicate worsening dyspnea, edema, dizziness, chest symptoms, or exercise intolerance through the heart-failure team.

Limitations & cautions

• Only eight trials were included, comparator types and program designs differed, and some estimates came from single studies or few trials. Evidence certainty ranged from low to moderate, follow-up was generally short, and sparse adverse events do not establish long-term safety, equivalence, or noninferiority to center-based rehabilitation.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The review included 10 randomized and cohort studies with 2,643 adult cardiac-surgery patients.
• PCC was associated with lower early red-cell transfusion use and less 12- to 24-hour chest-tube drainage than plasma.
• Mortality, thromboembolic events, stroke, acute kidney injury, and serious adverse events did not differ significantly.
• Mixed study designs and moderate to high heterogeneity limit certainty for several outcomes.

Nursing implications

• When PCC or plasma is ordered for post-cardiac-surgery bleeding, verify the product and administration plan and trend bleeding, chest-tube output, transfusion requirements, hemodynamics, and possible complications. Report unexpected bleeding or thrombotic concerns promptly; do not substitute one product for another from this review alone.

Limitations & cautions

• The analysis combined randomized trials and cohort studies, and several outcomes had moderate to high heterogeneity. Event estimates may be affected by differences in dosing, bleeding definitions, transfusion protocols, and patient risk. Nonsignificant safety outcomes do not establish equivalence, and the authors call for larger high-quality trials.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The trial randomized 8,250 patients at 97 centers after 12 event-free months following multivessel PCI.
• The composite ischemic outcome occurred in 5.8% with extended DAPT and 6.8% with aspirin alone at 36 months.
• Clinically relevant or major bleeding was 1.4% versus 1.5% and did not differ significantly.
• The findings apply to selected stable patients who tolerated the first year of dual therapy without major ischemic or bleeding events.

Nursing implications

• Confirm the intended antiplatelet duration during transitions of care and assess adherence, bleeding symptoms, interacting medicines, and upcoming procedures. Do not stop or extend therapy based on the study alone; route concerns to the cardiology or prescribing team.

Limitations & cautions

• The trial was open label, conducted at 97 centers in China, enrolled patients 18 to 75 years old, and selected only those without major ischemic or bleeding events during the first 12 months of DAPT. The findings may not generalize to higher-bleeding-risk patients, older adults, other regimens, or patients with an event during the first year.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The open-label trial enrolled 101 post-cardiac-surgery patients and analyzed 98.
• Virtual reality did not significantly reduce pain during chest-drain removal compared with usual care.
• State-anxiety differences were also not statistically significant.
• Mean satisfaction with the virtual-reality experience was high at 8.3 out of 10.

Nursing implications

• Do not assume that high patient satisfaction with virtual reality means it reduces procedural pain or anxiety. Continue facility-approved pain assessment and comfort measures for chest-drain removal, and evaluate any new distraction tool against clinical outcomes as well as acceptability.

Limitations & cautions

• This was an open-label, single-center study limited to spontaneously breathing patients who could communicate. The analysis included 98 patients, and the study does not establish whether different virtual-reality content, patient selection, or use alongside other interventions would change outcomes.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The single-center trial randomized 122 adults taking long-term warfarin for atrial fibrillation.
• The intervention combined routine education with WeChat and cloud-based nurse follow-up for six months.
• INR compliance and monitoring were higher at 10 days and 1 month, and medication adherence was higher with telehealth.
• The trial detected no significant difference in complications or readmissions.

Nursing implications

• A structured, approved telehealth pathway may help reinforce INR follow-up and medication adherence after discharge. Teams should still monitor bleeding, thromboembolic events, complications, and readmissions because better process measures did not translate into detected clinical-outcome differences in this small trial.

Limitations & cautions

• This was a single-center study of 122 patients in one Chinese cardiology department with six months of follow-up. The intervention combined education, WeChat contact, and cloud monitoring, and the study did not detect differences in complications or readmissions.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• The trial included 3,869 patients with suspected non-ST-elevation acute coronary syndrome across 12 hospitals and five countries.
• The intervention standardized high-sensitivity troponin T testing at baseline and 1 hour.
• Thirty-day major adverse cardiac events were 1.4% with the pathway and 1.7% with usual care, meeting the trial's noninferiority criterion.
• Emergency-department discharge increased from 35% to 60%, although three 30-day events occurred among 941 patients classified as low risk.

Nursing implications

• ED teams can use the findings when evaluating a locally approved 0/1-hour high-sensitivity troponin T pathway with clear eligibility, timing, interpretation, and escalation rules. The study does not support substituting a single result for the full protocol or applying its cutoffs to a different assay without validation.

Limitations & cautions

• This was a stepped-wedge cluster trial rather than individual randomization and used high-sensitivity troponin T in Asian emergency departments. Transfer to other populations, assays, cutoffs, and workflows requires local validation, and a small number of 30-day events still occurred among patients classified as low risk.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Among 126 adults with heart failure, 43 (34%) were physically frail.
• Better symptom monitoring (P = .037) and better symptom management (P = .023) were each associated with being physically frail, after adjusting for mortality risk.
• Physical frailty was associated with significantly worse 6-month clinical event risk regardless of how adequately patients monitored their symptoms.
• The authors suggest physical frailty may drive better self-care yet remains an independent marker of clinical risk.

Nursing implications

• For cardiology and telemetry nurses, the findings suggest that noticing physical frailty in heart failure patients, alongside teaching symptom monitoring, may help identify those at higher risk over the next six months. Because this was an observational study, frailty assessment should complement rather than replace existing risk tools and discharge teaching, and any change in care planning belongs with the heart failure team.

Limitations & cautions

• This was a single prospective observational cohort of 126 adults, so it shows associations rather than cause and effect, and cannot establish that addressing frailty changes outcomes. Symptom behaviors were self-reported, the sample was mostly NYHA Class III with nonischemic heart failure, and follow-up was limited to six months, so results may not generalise to all heart failure populations.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Among 1076 adults aged 40 or older with acute myocardial infarction, 19.0% presented without any chest-related symptoms.
• Reduced level of consciousness was independently associated with atypical presentation (odds ratio 4.93; 95% CI 2.41 to 10.05; P < .001).
• Greater functional dependence in activities of daily living was also independently associated (odds ratio 1.10; 95% CI 1.06 to 1.15; P < .001).
• Patients with atypical presentations tended to be older with lower body mass index and lower Glasgow Coma Scale scores.

Nursing implications

• For emergency nurses, the findings suggest a heart attack cannot be ruled out on the absence of chest pain alone, especially in older adults or those with reduced consciousness or high dependence in activities of daily living. Folding functional status and Glasgow Coma Scale into the triage picture, and keeping a lower threshold for cardiac workup in impaired patients, may help catch atypical presentations earlier.

Limitations & cautions

• This was a single-center retrospective cohort at one regional teaching hospital in Taiwan, drawing on electronic health record data from 2016 to 2023, so practice and documentation patterns may not generalize elsewhere. The observational design shows association, not causation, and only patients already diagnosed with acute myocardial infarction were included, so the study cannot speak to how often atypical presentations are missed entirely.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Weekly nurse-led phone follow-up cut HF-related rehospitalizations at 180 days from 46% to 26% (RR 0.56, P<0.02).
• Death or rehospitalization was also lower with the intervention (30% vs 47%; RR 0.63, P=0.04).
• Calls tracked weight, blood pressure, heart rate, decompensation signs, and adherence, paired with text-message education.
• The intervention worked in a high-risk, lower-literacy, lower-resource population (mean age 64; 65% NYHA class III/IV).

Nursing implications

• Before a heart failure patient leaves, reinforce daily morning weights and a clear 'call if you gain weight or get more short of breath' plan, and teach weight, blood pressure, heart rate, decompensation signs, and adherence as a bundle. Advocate for structured nurse-led phone follow-up, and don't assume low health literacy rules a patient out of it.

Limitations & cautions

• This was a small single-country trial (127 patients across six Brazilian public hospitals), so absolute event rates may not transfer directly elsewhere. An open-label behavioral intervention cannot be blinded and was not powered for mortality, so the survival signal should be read cautiously.
• AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

• Across 25 RCTs and 2,746 patients, nurse-led self-care improved quality of life, anxiety, and symptom burden.
• The anxiety benefit was supported by high-certainty evidence.
• No significant effect was seen on all-cause readmission or ED visits.
• Effects on mortality and sleep quality were unclear.

Nursing implications

• Prioritize structured heart failure self-care teaching such as daily weights, symptom tracking, sodium and fluid guidance, and medication adherence, use teach-back to confirm understanding, and set realistic expectations that the strongest gains were in quality of life and symptoms rather than readmissions.

Limitations & cautions

• Certainty varied by outcome, and effects on readmission and mortality were not demonstrated. Interventions differed across trials, so the exact dose of teaching that helps is unclear.
• AI-summarized from the linked source. Review the original article before applying to practice.